Drug-facilitated weight loss benefits cardiometabolic status

April 12, 2013
Drug-facilitated weight loss benefits cardiometabolic status
Obese and overweight patients with dyslipidemia or hypertension treated with phentermine and topiramate extended-release (PHEN/TPM ER) for weight loss had significant improvements in cardiovascular disease risk factors, according to research published in the April 15 issue of The American Journal of Cardiology.

(HealthDay)—Obese and overweight patients with dyslipidemia or hypertension treated with phentermine and topiramate extended-release (PHEN/TPM ER) for weight loss had significant improvements in cardiovascular disease risk factors, according to research published in the April 15 issue of The American Journal of Cardiology.

Michael H. Davidson, M.D., of University of Chicago, and colleagues conducted a subgroup analysis of subjects with either hyperlipidemia or hypertension who participated in the CONQUER study, a randomized, double-blind, placebo-controlled, multi-center study, to determine changes in cardiometabolic risk factors in subjects treated with PHEN/TPM ER.

According to the researchers, in a subgroup of 647 patients with dyslipidemia or hypertension, treatment with either low or high dose of PHEN/TPM ER resulted in significantly greater percentage weight loss than patients treated with placebo. Independent of treatments, significantly greater reductions in triglycerides (-14.5 percent to -39.8 percent) and non-high-density lipoprotein cholesterol (-9.4 percent to -14.8 percent) were observed in patients with dyslipidemia who lost ≥ 5 percent of their weight than those who lost < 5 percent of their baseline weight. Patients with hypertension who lost ≥ 5 percent of their weight also had significantly greater reductions in systolic blood pressure (-7.5 to -11.8 mm Hg).

"The dose-related weight loss induced by PHEN/TPM ER, the associated beneficial effects on cardiometabolic risk factors, and the reductions in medication use indicate that PHEN/TPM ER treatment may be an important addition to the therapeutic armamentarium for obese and with comorbidities such as hypertension and dyslipidemia," the authors write.

The study was supported by VIVUS, Inc., Mountain View, California and several authors disclosed with pharmaceutical and biotechnology companies.

Explore further: ECO: New weight loss drug effective in advanced obesity

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ECO: New weight loss drug effective in advanced obesity

May 14, 2012
(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related comorbidities, ...

Experimental drug helps diabetes patients lose weight

June 25, 2012
An experimental drug helped significantly more overweight patients with diabetes shed pounds, compared with placebo, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting in Houston.

Experimental drug achieves unprecedented weight loss

April 11, 2011
An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers ...

Fitness, obesity independently affect cardiometabolic risk

April 3, 2013
(HealthDay)—Fitness and obesity are independently associated with cardiometabolic (CM) risk, according to a study published in the April 1 issue of The American Journal of Cardiology.

Pediatric kidney disease tied to abnormal carotid arteries

September 28, 2012
(HealthDay)—Ultrasound measurements of carotid intima-media thickness (cIMT) are significantly elevated among children with chronic kidney disease (CKD) compared with healthy controls, according to a study published online ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.